Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Zogenix Inc (Zogenix) is a specialty pharmaceutical company that develops and markets therapies for the treatment of patients with rare diseases. The company’s marketed products include Fintepla (fenfluramine) approved in the US, the UK and EU for the treatment of seizures associated with the Dravet syndrome. Its pipeline product candidates include MT1621, intended for the treatment of thymidine kinase 2 deficiency (TK2d); Fintepla for Lennox-Gastaut syndrome (LGS) and other rare epilepsies; and gene therapies for Dravet syndrome and other types of epilepsy. The company operates through its subsidiaries in the US, the UK, Germany, Ireland, Japan, France and Italy. Zogenix is headquartered in Emeryville, California, the US.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Gain key insights into the company for academic or business research.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Zogenix Inc (Zogenix) is a specialty pharmaceutical company that develops and markets therapies for the treatment of patients with rare diseases. The company’s marketed products include Fintepla (fenfluramine) approved in the US, the UK and EU for the treatment of seizures associated with the Dravet syndrome. Its pipeline product candidates include MT1621, intended for the treatment of thymidine kinase 2 deficiency (TK2d); Fintepla for Lennox-Gastaut syndrome (LGS) and other rare epilepsies; and gene therapies for Dravet syndrome and other types of epilepsy. The company operates through its subsidiaries in the US, the UK, Germany, Ireland, Japan, France and Italy. Zogenix is headquartered in Emeryville, California, the US.
Zogenix Inc Key Recent Developments
- Mar 08, 2022: UCB concludes acquisition of biopharma firm Zogenix for $1.9bn
- Feb 28, 2022: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
- Feb 15, 2022: Zogenix supports new no-cost genetic testing program with United Mitochondrial Disease Foundation to improve diagnosis of mitochondrial diseases
- Jan 20, 2022: UCB to buy rare disease therapies developer Zogenix for $1.9bn
- Nov 04, 2021: Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Key benefits of buying this profile include:
- You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Wellstat Therapeutics Corp
- Supernus Pharmaceuticals Inc
- Stoke Therapeutics Inc
- Stealth BioTherapeutics Corp
- Sarepta Therapeutics Inc
- Reneo Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- PTC Therapeutics Inc
- Ovid Therapeutics Inc
- NeuroCycle Therapeutics Inc
- Neurocrine Biosciences Inc
- NeuCyte Inc
- Metro International Biotech LLC
- GW Pharmaceuticals Plc
- EpyGenix Therapeutics Inc
- Encoded Therapeutics Inc
- Biocodex